Non-invasive ventilation in acute respiratory failure of oncology-hematology patients : What are its current benefits and limitations?
Copyright © 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved..
Acute respiratory failure (ARF) is a leading cause, along with sepsis, of admission to the intensive care unit (ICU) of patients with active cancer. Presenting variable clinical severity, ARF in onco-hematological patients has differing etiologies, primarily represented by possibly opportunistic acute infectious pneumonia (de novo hypoxemic ARF), and decompensation in chronic cardiac or respiratory diseases (e.g., acute pulmonary edema or exacerbated chronic obstructive pulmonary disease). In these patients, orotracheal intubation is associated with a doubled risk of in-hospital mortality. Consequently, over the last three decades, numerous researchers have attempted to demonstrate and pinpoint the precise role of non-invasive ventilation (NIV) in the specific context of ARF in onco-hematological patients. While the benefits of NIV in the management of acute pulmonary edema or alveolar hypoventilation (hypercapnic ARF) are well-demonstrated, its positioning in de novo hypoxemic ARF is debatable, and has recently been called into question. In the early 2000s, based on randomized controlled trials, NIV was recommended as first-line treatment, one reason being that it allowed significantly reduced use of orotracheal intubation. In the latest randomized studies, however, the benefits of NIV in terms of survival orotracheal intubation have not been observed; as a result, it is no longer recommended in the management of de novo hypoxemic ARF in onco-haematological patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Revue des maladies respiratoires - (2024) vom: 11. Apr. |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Ventilation non invasive dans l’insuffisance respiratoire aiguë des patients d’onco-hématologie : quelle place en 2023 ? |
|---|
| Beteiligte Personen: |
Mayaux, J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 12.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.rmr.2024.03.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370990749 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370990749 | ||
| 003 | DE-627 | ||
| 005 | 20240413233139.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.rmr.2024.03.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1374.xml |
| 035 | |a (DE-627)NLM370990749 | ||
| 035 | |a (NLM)38609766 | ||
| 035 | |a (PII)S0761-8425(24)00171-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Mayaux, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Non-invasive ventilation in acute respiratory failure of oncology-hematology patients |b What are its current benefits and limitations? |
| 246 | 3 | 3 | |a Ventilation non invasive dans l’insuffisance respiratoire aiguë des patients d’onco-hématologie : quelle place en 2023 ? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Acute respiratory failure (ARF) is a leading cause, along with sepsis, of admission to the intensive care unit (ICU) of patients with active cancer. Presenting variable clinical severity, ARF in onco-hematological patients has differing etiologies, primarily represented by possibly opportunistic acute infectious pneumonia (de novo hypoxemic ARF), and decompensation in chronic cardiac or respiratory diseases (e.g., acute pulmonary edema or exacerbated chronic obstructive pulmonary disease). In these patients, orotracheal intubation is associated with a doubled risk of in-hospital mortality. Consequently, over the last three decades, numerous researchers have attempted to demonstrate and pinpoint the precise role of non-invasive ventilation (NIV) in the specific context of ARF in onco-hematological patients. While the benefits of NIV in the management of acute pulmonary edema or alveolar hypoventilation (hypercapnic ARF) are well-demonstrated, its positioning in de novo hypoxemic ARF is debatable, and has recently been called into question. In the early 2000s, based on randomized controlled trials, NIV was recommended as first-line treatment, one reason being that it allowed significantly reduced use of orotracheal intubation. In the latest randomized studies, however, the benefits of NIV in terms of survival orotracheal intubation have not been observed; as a result, it is no longer recommended in the management of de novo hypoxemic ARF in onco-haematological patients | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Acute respiratory failure (ARF) | |
| 650 | 4 | |a Infectious pneumonia | |
| 650 | 4 | |a Insuffisance respiratoire aiguë (IRA) | |
| 650 | 4 | |a Intubation orotrachéale | |
| 650 | 4 | |a Non-invasive ventilation (NIV) | |
| 650 | 4 | |a Oncologie-hématologie | |
| 650 | 4 | |a Oncology-hematology | |
| 650 | 4 | |a Orotracheal intubation | |
| 650 | 4 | |a Pneumonie infectieuse | |
| 650 | 4 | |a Ventilation non invasive (VNI) | |
| 700 | 1 | |a Decavele, M |e verfasserin |4 aut | |
| 700 | 1 | |a Dres, M |e verfasserin |4 aut | |
| 700 | 1 | |a Lecronier, M |e verfasserin |4 aut | |
| 700 | 1 | |a Demoule, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue des maladies respiratoires |d 1988 |g (2024) vom: 11. Apr. |w (DE-627)NLM012622443 |x 1776-2588 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:11 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmr.2024.03.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 11 |c 04 | ||